Last SFr.33.75 CHF
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:43 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT) Snapshot

Open
SFr.33.75
Previous Close
SFr.33.75
Day High
--
Day Low
--
52 Week High
05/28/13 - SFr.37.10
52 Week Low
10/8/13 - SFr.29.30
Market Cap
52.1B
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
04/11/14
P/E TM
--
Dividend
SFr.0.87
Dividend Yield
1.93%
Current Stock Chart for ABBOTT LABORATORIES (ABT)

abbott laboratories (ABT) Details

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products comprising various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

69,000 Employees
Last Reported Date: 04/16/14
Founded in 1888

abbott laboratories (ABT) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT) Key Developments

Abbott Laboratories Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Second Quarter and Full Year of 2014

Abbott Laboratories announced consolidated unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales of $5,244 million against $5,378 million a year ago. Operating earnings were $615 million against $615 million a year ago. Net earnings from continuing operations was $339 million against $544 million a year ago. Earnings from continuing operations before taxes were $423 million against $554 million a year ago. Net earnings were $375 million against $544 million a year ago. Net Earnings from continuing operations excluding specified items were $641 million against $674 million a year ago. Diluted earnings per common share from continuing operations were $0.22 against $0.34 a year ago. Diluted earnings per common share were $0.24 against $0.34 a year ago. Excluding special charges, it earned 41 cents per share. For the second quarter of 2014, the company is forecasting ongoing earnings per share of $0.50 to $0.52, reflecting double-digit growth at the midpoint of the range. The company is forecasting operational sales growth in the low to mid-single digits in the second quarter. At current exchange rate, the company expects a negative impact from exchange of approximately 1.5%, resulting in reported sales in the low single digits. The company forecasts an adjusted gross margin ratio of around 54.5% of sales. The company announced that it is confirming ongoing earnings-per-share guidance for the full-year of 2014 of $2.16 to $2.26, representing double-digit growth at the mid-point of the guidance range. Abbott continues to forecast net specified items for the full year 2014 of $1.03 per share. Including these net specified items, projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) would be $1.13 to $1.23 for the full year 2014. The company forecasts an adjusted gross margin ratio of approximately 55% of sales for the full year, which reflects a negative impact of around 50 basis points from foreign exchange.

Abbott Laboratories to Open 3 New Manufacturing Facilities in China, India and the United States

Abbott Laboratories expect to open 3 new manufacturing facilities in the second quarter this year in China, India and the United States to support strong global demand for the products, and the remain on track to achieve an operating margin ratio of more than 20% of sales in the Nutrition business by 2015.

Abbott Announces FDA Clearance for New Test to Help Physicians Quickly and Accurately Diagnose Diabetes

Abbott announced that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test -- which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease -- has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ARCHITECT clinical chemistry HbA1c test is now available in several countries throughout Europe, Asia, Latin America, Canada and Africa, pending country registration. The test will be available in the U.S. in the coming weeks. The ARCHITECT HbA1c assay is used in clinical laboratories for the quantitative in vitro measurement of the percent hemoglobin A1c (% HbA1c) or the hemoglobin A1c concentration (mmol/mol) in human whole blood and hemolysate on the ARCHITECT c8000 System. Hemoglobin A1c measurements are used as an aid in the diagnosis of diabetes mellitus, to identify patients who may be at risk for developing diabetes mellitus, and for the monitoring of long-term blood glucose control in individuals with diabetes mellitus. Hemoglobin A1c should not be used for the diagnosis of diabetes in patients with abnormal red cell turnover, such as pregnancy, recent blood loss or transfusion, or some types of anemia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:SW SFr.33.75 CHF 0.00

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $48.55 USD +0.43
Danaher Corp $72.85 USD -0.80
Eli Lilly & Co $60.43 USD +0.47
Medtronic Inc $58.55 USD +0.06
Teva Pharmaceutical Industries Ltd $50.85 USD +0.94
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 28.2x
Price/Sales 2.8x
Price/Book 2.4x
Price/Cash Flow 18.9x
TEV/Sales 2.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.